Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

   
   

The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

De onderhavige uitvinding verstrekt methodes van behandeling en preventie van vroege hart en vroege cardiovasculaire ziekten, bijvoorbeeld van ischemische oorsprong, zoals linker ventriculaire hypertrofie, kransslagaderziekte, essentiƫle hypertensie, scherpe noodsituatie met te hoge bloeddruk, cardiomyopathie, hartontoereikendheid, oefeningstolerantie, chronische hartverlamming, aritmie, hartdysrhythmia, syncopy, arteriosclerose, milde chronische hartverlamming, angina pectoris, hartomleidingsreocclusion, intermitterende claudication (arteriosclerose oblitterens), diastolische dysfunctie en systolische dysfunctie, evenals verbeterend het succes van hartoverplantingen, door beleid van glycogeenphosphorylase inhibitorsamenstellingen.

 
Web www.patentalert.com

< Use of sugar phosphates, sugar phosphate analog, amino acids, amino acid analogs for modulating transaminases and/or the association of p36/ malate dehydrogenase

< Method and system for rapidly conferring a desired trait to an organism

> 2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

> Azepinoindole derivatives as pharmaceutical agents

~ 00167